Department of Dentistry and Oral Surgery, Unit of Sensory and Locomotor Medicine, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Division of Infection Control, University of Fukui Hospital, Fukui, Japan; Department of Pharmacy, University of Fukui Hospital, Fukui, Japan.
J Infect Chemother. 2020 Jun;26(6):531-534. doi: 10.1016/j.jiac.2020.01.003. Epub 2020 Jan 30.
Oral antibiotic therapy is routinely administered when a third molar (M3) is extracted to prevent infectious complications after surgery. Oral third-generation cephalosporins are frequently used after M3 extraction in Japan but at the expense of an increased risk of antimicrobial resistance. Therefore, the infection control team (ICT) at our institution recommended a reduction in use of these agents after M3 extraction. In this study, we compared the types of antibiotic agents prescribed for patients undergoing M3 extraction before and after this recommendation. We investigated the relationship between type of antibiotic used and the likelihood of infectious complications as well as cost savings in patients who underwent M3 extraction in the 6 months before and after the ICT recommendation in July 2018. There was a marked reduction in use of oral third-generation cephalosporins after M3 extraction (P < 0.0001) and increased use of oral penicillins and first-generation cephalosporins after the ICT recommendation. Moreover, surgical site infection (SSIs) were significantly less common after the ICT recommendation (P = 0.0099); however, the SSI rate was higher in patients who received a third-generation cephalosporin than in those who received penicillin (8.8% vs 0.5%). There was also a significant saving in per-patient antibiotic costs after the ICT recommendation (269.5 ± 282.0 JPY vs 454.7 ± 376.6 JPY; P < 0.0001). These findings suggest that collaboration with an ICT promotes appropriate antibiotic use, decreases the risk of an SSI, and improves the cost-benefit ratio in patients undergoing M3 extraction.
在拔除第三磨牙(M3)后,通常会给予口服抗生素治疗,以预防手术后的感染性并发症。在日本,拔除 M3 后常使用第三代口服头孢菌素,但这会增加抗菌药物耐药的风险。因此,我院感染控制团队(ICT)建议减少 M3 拔除术后这些药物的使用。在这项研究中,我们比较了 M3 拔除术前和术后患者处方的抗生素类型。我们调查了使用的抗生素类型与感染性并发症的发生几率之间的关系,以及在 2018 年 7 月 ICT 建议前后 6 个月内接受 M3 拔除术的患者的成本节约情况。M3 拔除术后第三代口服头孢菌素的使用明显减少(P<0.0001),ICT 建议后口服青霉素和第一代头孢菌素的使用增加。此外,ICT 建议后手术部位感染(SSI)明显减少(P=0.0099);然而,接受第三代头孢菌素的患者 SSI 发生率高于接受青霉素的患者(8.8%比 0.5%)。ICT 建议后,每位患者的抗生素费用也有显著节省(269.5±282.0 JPY 比 454.7±376.6 JPY;P<0.0001)。这些发现表明,与 ICT 合作可促进合理使用抗生素,降低 SSI 风险,并提高接受 M3 拔除术的患者的成本效益比。